Results for: COVID-19 vaccine

A Utah mother, Brianne Dressen, alleges that the pharmaceutical company AstraZeneca breached a contract that promised compensation for injuries sustained during a clinical trial for the COVID-19 vaccine. After experiencing severe adverse effects from the vaccine, Dressen was left with mounting medical bills and claims that AstraZeneca has failed to provide adequate support. The lawsuit, filed in the U.S., is the first of its kind against AstraZeneca regarding the coronavirus vaccine trial. Dressen’s aim is to hold the company accountable and raise awareness about the potential risks associated with clinical trials and the need for proper compensation for participants who suffer injuries.

AstraZeneca’s COVID-19 vaccine, in collaboration with Oxford University, has been found to increase the risk of a rare but deadly blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT). The condition, characterized by the presence of a specific blood autoantibody targeting platelet factor 4 (PF4), was initially observed following the administration of the Oxford-AstraZeneca vaccine, also known as Covishield in India and Vaxzevria in Europe. Researchers have since discovered that PF4 antibodies can also trigger VITT in cases of natural adenovirus infections. AstraZeneca has also announced positive results from a late-stage trial of sipavibart, a long-acting antibody therapy that has shown promise in reducing the risk of infection among immunocompromised individuals.

In response to concerns regarding potential side effects of Covishield, Bharat Biotech has released a statement emphasizing the extensive safety and efficacy measures implemented during the development of their COVID-19 vaccine. The company has stressed its commitment to adhering to rigorous scientific protocols and regulatory standards throughout the vaccine’s development and evaluation process.

The government is considering allowing mothers to report side effects of routine immunizations on the U-WIN platform. This move aligns with the admission by AstraZeneca that its COVID-19 vaccine, Covishield, can rarely induce blood clots. The U-WIN platform, similar to CoWIN for COVID-19, tracks vaccinations and immunization. Currently in a pilot phase, U-WIN is expected to become the world’s largest electronic immunization system, aiming to improve vaccination coverage and reduce infant mortality. As part of the integration with Ayushman Bharat Digital Mission, healthcare providers will have access to patients’ complete health records.

Pharmaceutical giant AstraZeneca has admitted that its Covid-19 vaccine can cause a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). The admission was made in court documents for the first time since the vaccine was rolled out. The company, which developed the vaccine in partnership with the University of Oxford, is facing a class-action lawsuit alleging that their vaccine has resulted in fatalities and serious injuries among recipients. Victims and grieving relatives are seeking damages estimated to be worth up to £100 million.

Moderna Inc. has filed a patent infringement lawsuit against Pfizer Inc. and BioNTech SE in a London court, alleging that the companies’ COVID-19 vaccine infringes on Moderna’s mRNA technology patents. Pfizer and BioNTech have denied the allegations and asserted that their patent is invalid. The outcome of the lawsuit could have significant implications for the mRNA vaccine market and the future of mRNA-based products.

Moderna has secured a contract with Brazil’s Ministry of Health to supply 12.5 million doses of its mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. The agreement marks Moderna’s first-time contribution to Brazil’s vaccination efforts. The vaccine is expected to be delivered in the second quarter of 2024.